Inclusion Criteria~The aMCI participant must meet all of the inclusion criteria to be eligible for this
clinical trial:~1. Male or female participants of any race or ethnicity~2. Inpatients or outpatients 60 to 75
years of age (on day of randomization)~3. Diagnosis of MCI based on DSM 5 diagnostic criteria of Minor
Neurocognitive Disorder~4. Categorization of episodic memory impairment based on scores â‰¥ 1.0 SD lower on any
of the following measures in comparison to normative data i. Logical Memory Test (62), ii. California Verbal
Learning Test (63), iii. Modified Rey-Osterrieth Complex Figure (64).~5. Non-smoker/Non-nicotine user~6.
Montreal Cognitive Assessment (MoCA) score = < 26 and MMSE score > = 24~7. Capable of consenting to participate
in the research study~8. On a stable dose of medication for at least 2 months \[see section 5.6\], and unlikely
to undergo changes in dose during the study~9. Availability of a study partner who has regular contact with the
participant~10. Ability to read and communicate in English (with corrected vision and hearing, if needed)~The
Healthy Control participant must meet all of the inclusion criteria to be eligible for this clinical trial:~1.
Male or female participants of any race or ethnicity~2. 60 to 75 years of age (on day of randomization)~3. Does
not meet SCID-5 criteria for Mild Neurocognitive Disorder, Alzheimer's disease, or other major neurocognitive
disorder~4. Non-smoker/Non-nicotine user~5. Capable of consenting to participate in the research study~6. On a
stable dose of medication for at least 2 months \[see section 5.6\], and unlikely to undergo changes in dose
during the study~7. Availability of a study partner who has regular contact with the participant~8. Ability to
read and communicate in English (with corrected vision and hearing, if needed)~
